Delcath Systems (DCTH) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avita Medical (RCEL) has outperformed Delcath Systems (DCTH) over the past year, gaining 312.1% versus a gain of 109.7%. Over five years, DCTH leads with a +92.9% price change compared with +10.8% for RCEL. Delcath Systems is the larger company by market cap ($653.7 million vs $495.0 million), about 1.3 times the size.
Delcath Systems converts more of its revenue into profit, with a net margin of 3.2% versus -67.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | RCEL |
|---|---|---|
| Share price | $18.79 | $15.62 |
| Market cap | $653.67M | $494.96M |
| 1-day change | -2.34% | -2.31% |
| YTD return | +86.04% | +352.75% |
| 1-year return | +109.71% | +312.14% |
| 5-year return | +92.92% | +10.78% |
| P/E ratio (TTM) | 117.44 | — |
| Forward P/E | 68.95 | — |
| EPS (TTM) | $0.16 | $-1.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.23M | $71.61M |
| Revenue growth (YoY) | +129.08% | +11.45% |
| Net income (latest FY) | $2.70M | $-48.59M |
| Gross margin | 86.16% | 82.13% |
| Operating margin | 0.77% | -59.40% |
| Net margin | 3.17% | -67.85% |
| 52-week high | $22.51 | $18.43 |
| 52-week low | $8.49 | $3.22 |
| Distance from 52-week high | -16.53% | -15.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +52.21% | +32.46% |
| Average volume | 497.48K | 417.02K |
| Shares outstanding | 34.79M | 31.69M |
| Employees | 156 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed DCTH by 202.4 percentage points over the past year.
- Delcath Systems is more profitable, keeping 3.2 cents of every revenue dollar as net income versus -67.8 cents for Avita Medical.
- Delcath Systems grew revenue faster in its latest fiscal year (+129.08% vs +11.45%).
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
DCTH vs RCEL FAQ
Which is bigger, Delcath Systems or Avita Medical?
Delcath Systems (DCTH) is larger, with a market capitalization of $653.67M compared with $494.96M for Avita Medical (RCEL).
Which stock has performed better over the past year, DCTH or RCEL?
RCEL returned +312.14% over the past 12 months, compared with +109.71% for DCTH (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.